Article
Presented by Ralph Buttyan, PhD, Columbia-Presbyterian MedicalCenter, New York.
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
“Go big or go small”: Current and emerging tools in kidney stone management
Minimal approach to WVTT linked to favorable post-operative outcomes
FDA clears stapler for use with da Vinci SP surgical system
Polygenic risk score may identify more clinically significant PCa than PSA, MRI
